Published in Curr Opin Neurobiol on June 01, 2002
Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem J (2003) 2.89
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J (2004) 1.89
IL-2 production in developing Th1 cells is regulated by heterodimerization of RelA and T-bet and requires T-bet serine residue 508. J Exp Med (2005) 1.64
Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J Cell Biol (2005) 1.59
Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3. J Biol Chem (2007) 1.37
GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev (2007) 1.36
Insulin receptor signaling in the development of neuronal structure and function. Neural Dev (2010) 1.29
Molecular targets of opiate drug abuse in neuroAIDS. Neurotox Res (2005) 1.16
Overexpression of glycogen synthase kinase 3beta sensitizes neuronal cells to ethanol toxicity. J Neurosci Res (2009) 1.02
GSK3beta in ethanol neurotoxicity. Mol Neurobiol (2009) 1.01
Disease-associated mutations inactivate AMP-lysine hydrolase activity of Aprataxin. J Biol Chem (2005) 1.00
Concerted perturbation observed in a hub network in Alzheimer's disease. PLoS One (2012) 1.00
Molecular mechanisms of environmental enrichment: impairments in Akt/GSK3β, neurotrophin-3 and CREB signaling. PLoS One (2013) 0.97
Cell signaling underlying epileptic behavior. Front Behav Neurosci (2011) 0.96
Phosphorylation of neuronal survival factor MEF2D by glycogen synthase kinase 3beta in neuronal apoptosis. J Biol Chem (2009) 0.96
Huntington's disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads database. BMC Neurol (2012) 0.96
Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. ACS Chem Neurosci (2012) 0.96
GSK-3 phosphorylates delta-catenin and negatively regulates its stability via ubiquitination/proteosome-mediated proteolysis. J Biol Chem (2009) 0.93
Up-regulation of GRP78 and antiapoptotic signaling in murine peritoneal macrophages exposed to insulin. J Leukoc Biol (2005) 0.89
The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers. BMC Neurosci (2009) 0.88
Reelin signaling in development, maintenance, and plasticity of neural networks. Ageing Res Rev (2013) 0.87
Overexpression of alpha-synuclein down-regulates BDNF expression. Cell Mol Neurobiol (2010) 0.87
Activity-dependent regulation of dendritic growth and maintenance by glycogen synthase kinase 3β. Nat Commun (2013) 0.86
Steroid hormone release as well as renal water and electrolyte excretion of mice expressing PKB/SGK-resistant GSK3. Pflugers Arch (2008) 0.84
Dynamic change of SGK expression and its role in neuron apoptosis after traumatic brain injury. Int J Clin Exp Pathol (2013) 0.83
Akt isoforms differentially protect against stroke-induced neuronal injury by regulating mTOR activities. J Cereb Blood Flow Metab (2013) 0.82
Activation of GSK-3β and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine. PLoS One (2013) 0.82
Human neural stem cells alleviate Alzheimer-like pathology in a mouse model. Mol Neurodegener (2015) 0.81
Glycogen synthase kinase 3: a point of integration in Alzheimer's disease and a therapeutic target? Int J Alzheimers Dis (2012) 0.81
Morphine enhances HIV-1SF162-mediated neuron death and delays recovery of injured neurites. PLoS One (2014) 0.80
Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model. PLoS One (2014) 0.78
A novel mass spectrometry-based assay for GSK-3beta activity. BMC Biochem (2005) 0.77
Isorhynchophylline Protects PC12 Cells Against Beta-Amyloid-Induced Apoptosis via PI3K/Akt Signaling Pathway. Evid Based Complement Alternat Med (2013) 0.77
GSK3β-activation is a point of convergence for HIV-1 and opiate-mediated interactive neurotoxicity. Mol Cell Neurosci (2015) 0.77
Modulation of Neuronal Survival Factor MEF2 by Kinases in Parkinson's Disease. Front Physiol (2012) 0.77
The role of GSK3beta in the development of the central nervous system. Front Biol (Beijing) (2012) 0.77
Endogenous repair by the activation of cell survival signalling cascades during the early stages of rat Parkinsonism. PLoS One (2012) 0.76
Compartmental protein expression of Tau, GSK-3beta and TrkA in cholinergic neurons of aged rats. J Neural Transm (Vienna) (2006) 0.75
Glycogen synthase kinase 3 regulates expression of nuclear factor-erythroid-2 related transcription factor-1 (Nrf1) and inhibits pro-survival function of Nrf1. Exp Cell Res (2013) 0.75
Decreased store operated Ca2+ entry in dendritic cells isolated from mice expressing PKB/SGK-resistant GSK3. PLoS One (2014) 0.75
Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias. Mol Brain (2016) 0.75
(-)-SCR1693 Protects against Memory Impairment and Hippocampal Damage in a Chronic Cerebral Hypoperfusion Rat Model. Sci Rep (2016) 0.75
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med (2004) 4.63
Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature (2008) 3.68
ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell (2006) 3.39
RORalpha-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell (2006) 2.80
Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell (2003) 2.50
Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron (2003) 2.39
Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J Neurosci (2004) 2.29
The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins. Cell (2005) 2.09
A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron (2002) 1.97
Exercise and genetic rescue of SCA1 via the transcriptional repressor Capicua. Science (2011) 1.96
Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J Biol Chem (2008) 1.92
miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nat Neurosci (2008) 1.89
Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle. Genes Dev (2006) 1.65
Gene profiling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice. Hum Mol Genet (2004) 1.61
SCA1-like disease in mice expressing wild-type ataxin-1 with a serine to aspartic acid replacement at residue 776. Neuron (2010) 1.56
Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med (2007) 1.52
Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis. PLoS Genet (2010) 1.42
Polyglutamine disease toxicity is regulated by Nemo-like kinase in spinocerebellar ataxia type 1. J Neurosci (2013) 1.41
Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nat Genet (2007) 1.30
Mapmodulin/leucine-rich acidic nuclear protein binds the light chain of microtubule-associated protein 1B and modulates neuritogenesis. J Biol Chem (2003) 1.28
The unstable repeats--three evolving faces of neurological disease. Neuron (2013) 1.26
RNA association and nucleocytoplasmic shuttling by ataxin-1. J Cell Sci (2005) 1.21
Emerging pathogenic pathways in the spinocerebellar ataxias. Curr Opin Genet Dev (2009) 1.17
SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal. J Biol Chem (2005) 1.15
ATXN1 protein family and CIC regulate extracellular matrix remodeling and lung alveolarization. Dev Cell (2011) 1.12
Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci (2010) 1.12
The insulin-like growth factor pathway is altered in spinocerebellar ataxia type 1 and type 7. Proc Natl Acad Sci U S A (2008) 1.11
Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci (2011) 1.08
Targeted deletion of a single Sca8 ataxia locus allele in mice causes abnormal gait, progressive loss of motor coordination, and Purkinje cell dendritic deficits. J Neurosci (2006) 1.04
Partial loss of Tip60 slows mid-stage neurodegeneration in a spinocerebellar ataxia type 1 (SCA1) mouse model. Hum Mol Genet (2011) 1.02
Abnormalities in the climbing fiber-Purkinje cell circuitry contribute to neuronal dysfunction in ATXN1[82Q] mice. J Neurosci (2011) 1.01
Regional differences of somatic CAG repeat instability do not account for selective neuronal vulnerability in a knock-in mouse model of SCA1. Hum Mol Genet (2003) 1.00
Generation and characterization of LANP/pp32 null mice. Mol Cell Biol (2004) 1.00
Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3epsilon haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration. Proc Natl Acad Sci U S A (2011) 0.96
The effects of the polyglutamine repeat protein ataxin-1 on the UbL-UBA protein A1Up. J Biol Chem (2004) 0.95
14-3-3 Binding to ataxin-1(ATXN1) regulates its dephosphorylation at Ser-776 and transport to the nucleus. J Biol Chem (2011) 0.94
In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 mice. Exp Neurol (2011) 0.92
Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference. Ann Neurol (2014) 0.92
Phosphorylation of ATXN1 at Ser776 in the cerebellum. J Neurochem (2009) 0.91
Characterization of the zebrafish atxn1/axh gene family. J Neurogenet (2008) 0.87
Purkinje cell ataxin-1 modulates climbing fiber synaptic input in developing and adult mouse cerebellum. J Neurosci (2013) 0.87
Fragile X tremor/ataxia syndrome: blame the messenger! Neuron (2007) 0.84
Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias. Brain Res Bull (2011) 0.84
Hsp70/Hsc70 regulates the effect phosphorylation has on stabilizing ataxin-1. J Neurochem (2007) 0.84
Neurodegenerative disease: cut to the chase. Nature (2006) 0.84
Identification of a novel phosphorylation site in ataxin-1. Biochim Biophys Acta (2004) 0.83
A cell-based screen for modulators of ataxin-1 phosphorylation. Hum Mol Genet (2005) 0.82
Neurodegenerative disease: neuron protection agency. Nature (2004) 0.81
Amino acids in a region of ataxin-1 outside of the polyglutamine tract influence the course of disease in SCA1 transgenic mice. Neuromolecular Med (2002) 0.81
Antisense RNA sequences modulating the ataxin-1 message: molecular model of gene therapy for spinocerebellar ataxia type 1, a dominant-acting unstable trinucleotide repeat disease. Cell Transplant (2008) 0.80
Overexpression of CREB reduces CRE-mediated transcription: behavioral and cellular analyses in transgenic mice. Mol Cell Neurosci (2004) 0.77
Regulation of ataxin-1 phosphorylation and its impact on biology. Methods Mol Biol (2013) 0.77
A proposed mechanism of ALS fails the test in vivo. Nat Neurosci (2002) 0.75